Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2021, Vol. 12 Issue (1) : 36-41     DOI: 10.14336/AD.2020.0602
Commentary |
Interdisciplinary Research in Alzheimer’s Disease and the Roles International Societies Can Play
Shawn Zheng Kai Tan1, Robert Chunhua Zhao2,3,4, Sasanka Chakrabarti2,3,5,*, Ilia Stambler2,3,6,*, Kunlin Jin2,3,7,*, Lee Wei Lim1,2,3,*
1Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
2International Society on Aging and Disease (ISOAD), Fort Worth, Texas, USA.
3The Executive Committee on Anti-aging and Disease Prevention in the framework of Science and Technology, Pharmacology and Medicine Themes under an Interactive Atlas along the Silk Roads, UNESCO, Paris, France.
4School of Life Sciences, Shanghai University, Shanghai, China.
5Department of Biochemistry and Central Research Cell, M M Institute of Medical Sciences and Research, Mullana, India.
6The Geriatric Medical Center "Shmuel Harofe", Beer Yaakov, affiliated to Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
7Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Texas, USA.
Download: PDF(370 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

An ever-increasing ageing population has elevated Alzheimer’s disease to be one of the biggest challenges in modern medicine. Alzheimer’s disease is highly complex, and we are still no closer to understanding the causes, let alone an effective treatment. The lack of good experimental models and lack of critical understanding has led to high failure rates of clinical trials with high associated costs, as well as difficulties in implementing treatments. The multifaceted nature of this disease highlights the need for an interdisciplinary approach to address these concerns. In this essay, we suggest how collaborative work can be useful in addressing some of the above issues. We then propose that international organisations and publishers need to support interdisciplinary research by creating platforms, lobbying funders, and pushing for interdisciplinary publications. We further highlight some of the issues involved in implementing these suggestions and argue that willpower of the research community, together with a re-evaluation of evaluation metrics and incentive systems, are needed in order to foster interdisciplinary research. Overall, we emphasise the need for interdisciplinary research in Alzheimer’s disease and suggest that international societies should play a huge role in this endeavour.

Keywords Alzheimer’s disease      international societies      interdisciplinary      research     
Corresponding Authors: Chakrabarti Sasanka,Stambler Ilia,Jin Kunlin,Lim Lee Wei   
About author:

These authors contributed equally to the work.

Just Accepted Date: 04 June 2020   Issue Date: 11 January 2021
E-mail this article
E-mail Alert
Articles by authors
Tan Shawn Zheng Kai
Zhao Robert Chunhua
Chakrabarti Sasanka
Stambler Ilia
Jin Kunlin
Lim Lee Wei
Cite this article:   
Tan Shawn Zheng Kai,Zhao Robert Chunhua,Chakrabarti Sasanka, et al. Interdisciplinary Research in Alzheimer’s Disease and the Roles International Societies Can Play[J]. Aging and disease, 2021, 12(1): 36-41.
URL:     OR
[1] Qiu C, Kivipelto M, von Strauss E (2009). Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci, 11:111-128.
[2] Alzheimer's A (2015). 2015 Alzheimer's disease facts and figures. Alzheimers Dement, 11:332-384.
[3] Poon CH, Wang Y, Fung ML, Zhang C, Lim LW (2020). Rodent Models of Amyloid-Beta Feature of Alzheimer's Disease: Development and Potential Treatment Implications. Aging Dis, in press.
[4] Wong KY, Roy J, Fung ML, Heng BC, Zhang C, Lim LW (2020). Relationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer's Disease. Aging Dis, in press.
[5] Chakrabarti S, Khemka VK, Banerjee A, Chatterjee G, Ganguly A, Biswas A (2015). Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. Aging Dis, 6:282-299.
[6] Yuen RMF (2017). The Challenges of an Ageing Society from a Health Care Perspective. Public Adm Policy, 17:1-14.
[7] Cummings JL, Morstorf T, Zhong K (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 6:37.
[8] Cummings J (2010). What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease? Biol Psychiatry, 68:876-878.
[9] Leuzy A, Gauthier S (2012). Ethical issues in Alzheimer's disease: an overview. Expert Rev Neurother, 12:557-567.
[10] Mackey T (2003). An ethical assessment of anti-aging medicine. J Anti Aging Med, 6:187-204.
[11] Szell M, Ma YF, Sinatra R (2018). A Nobel opportunity for interdisciplinarity. Nat Phys, 14:1075-1078.
[12] Bromham L, Dinnage R, Hua X (2016). Interdisciplinary research has consistently lower funding success. Nature, 534:684-+.
[13] Ledford H (2015). How to solve the world's biggest problems. Nature, 525:308-311.
[14] Leahey E, Beckman CM, Stanko TL (2017). Prominent but Less Productive: The Impact of Interdisciplinarity on Scientists' Research. Adm Sci Q, 62:105-139.
[15] Korczyn AD (2012). Why have we Failed to Cure Alzheimer's Disease? J Alzheimers Dis, 29:275-282.
[16] Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998). Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol, 57:1168-1174.
[17] Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66:1837-1844.
[18] Karran E, Mercken M, De Strooper B (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov, 10:698-712.
[19] Braak H, Braak E (1995). Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging, 16:271-278; discussion 278-284.
[20] Drummond E, Wisniewski T (2017). Alzheimer's disease: experimental models and reality. Acta Neuropathol, 133:155-175.
[21] Liu A, Jain N, Vyas A, Lim LW (2015). Ventromedial prefrontal cortex stimulation enhances memory and hippocampal neurogenesis in the middle-aged rats. Elife, 4:e04803.
[22] Gallagher M, Burwell R, Burchinal M (1993). Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav Neurosci, 107:618-626.
[23] Mullane K, Williams M (2019). Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity. Curr Protoc Pharmacol, 84:e57.
[24] Mizuno S, Iijima R, Ogishima S, Kikuchi M, Matsuoka Y, Ghosh S, et al. (2012). AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst Biol, 6:52.
[25] Hallock P, Thomas MA (2012). Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. OMICS, 16:37-49.
[26] Geerts H, Hofmann-Apitius M, Anastasio TJ, Brain Health Modeling I (2017). Knowledge-driven computational modeling in Alzheimer's disease research: Current state and future trends. Alzheimers Dement, 13:1292-1302.
[27] Bai Z, Han G, Xie B, Wang J, Song F, Peng X, et al. (2016). AlzBase: an Integrative Database for Gene Dysregulation in Alzheimer's Disease. Mol Neurobiol, 53:310-319.
[28] De Strooper B, Karran E (2016). The Cellular Phase of Alzheimer's Disease. Cell, 164:603-615.
[29] Abu-Hassan K, Taylor JD, Morris PG, Donati E, Bortolotto ZA, Indiveri G, et al. (2019). Optimal solid state neurons. Nat Commun, 10:5309.
[30] Scott TJ, O'Connor AC, Link AN, Beaulieu TJ (2014). Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann N Y Acad Sci, 1313:17-34.
[31] Cummings J, Reiber C, Kumar P (2018). The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimers Dement (N Y), 4:330-343.
[32] Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. (2017). The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement, 13:1-7.
[33] El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. (2019). Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis, 70:323-341.
[34] Gardner RC, Valcour V, Yaffe K (2013). Dementia in the oldest old: a multi-factorial and growing public health issue. Alzheimers Res Ther, 5:27.
[35] Stone SS, Teixeira CM, Devito LM, Zaslavsky K, Josselyn SA, Lozano AM, et al. (2011). Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci, 31:13469-13484.
[36] Tan SZK, Fung ML, Koh J, Chan YS, Lim LW (2020). The Paradoxical Effect of Deep Brain Stimulation on Memory. Aging Dis, 11:179-190.
[37] Poon CH, Chan YS, Fung ML, Lim LW (2020). Memory and neuromodulation: A perspective of DNA methylation. Neurosci Biobehav Rev, 111:57-68.
[38] Groiss SJ, Wojtecki L, Sudmeyer M, Schnitzler A (2009). Deep brain stimulation in Parkinson's disease. Ther Adv Neurol Disord, 2:20-28.
[39] Kim MR, Yun JY, Jeon B, Lim YH, Kim KR, Yang HJ, et al. (2016). Patients' reluctance to undergo deep brain stimulation for Parkinson's disease. Parkinsonism Relat Disord, 23:91-94.
[40] Mosley PE, Breakspear M, Coyne T, Silburn P, Smith D (2018). Caregiver burden and caregiver appraisal of psychiatric symptoms are not modulated by subthalamic deep brain stimulation for Parkinson's disease. NPJ Parkinsons Dis, 4:12.
[41] Howe EG (2006). Ethical issues in diagnosing and treating Alzheimer disease. Psychiatry (Edgmont), 3:43-53.
[42] Sood P, Kletzel SL, Krishnan S, Devos H, Negm A, Hoffecker L, et al. (2019). Nonimmersive Brain Gaming for Older Adults With Cognitive Impairment: A Scoping Review. Gerontologist, 59:e764-e781.
[43] Mancioppi G, Fiorini L, Timpano Sportiello M, Cavallo F (2019). Novel Technological Solutions for Assessment, Treatment, and Assistance in Mild Cognitive Impairment. Front Neuroinform, 13:58.
[44] Astell AJ, Bouranis N, Hoey J, Lindauer A, Mihailidis A, Nugent C, et al. (2019). Technology and Dementia: The Future is Now. Dement Geriatr Cogn Disord, 47:131-139.
[45] Chiu CY, Kwan LYY, Liou SN (2013). Culturally Motivated Challenges to Innovations in Integrative Research: Theory and Solutions. Soc Issues Policy Rev, 7:149-172.
[46] Knapp B, Bardenet R, Bernabeu MO, Bordas R, Bruna M, Calderhead B, et al. (2015). Ten simple rules for a successful cross-disciplinary collaboration. PLoS Comput Biol, 11:e1004214.
[47] Boland MR, Karczewski KJ, Tatonetti NP (2017). Ten Simple Rules to Enable Multi-site Collaborations through Data Sharing. PLoS Comput Biol, 13.
[48] Vicens Q, Bourne PE (2007). Ten simple rules for a successful collaboration. PLoS Comput Biol, 3:335-336.
[49] Urbanska K, Huet S, Guimond S (2019). Does increased interdisciplinary contact among hard and social scientists help or hinder interdisciplinary research? PLos One, 14.
[50] Bruce CR (2013). A review of ethical considerations for ventricular assist device placement in older adults. Aging Dis, 4:100-112.
[51] Hubbard WJ, Dashti N (2011). Aging and transplantation - a topic for biomedicine or bioethics? Aging Dis, 2:181-185.
[52] Marx W, Bornmann L (2015). On the causes of subject-specific citation rates in Web of Science. Scientometrics, 102:1823-1827.
[53] Patience GS, Patience CA, Blais B, Bertrand F (2017). Citation analysis of scientific categories. Heliyon, 3:e00300.
[54] Jin KL, Simpkins JW, Ji XM, Leis M, Stambler I (2015). The Critical Need to Promote Research of Aging and Aging-related Diseases to Improve Health and Longevity of the Elderly Population. Aging Dis, 6:1-5.
[1] Yuhong Li,Hui Huang,Man Zhu,Hua Bai,Xiaowei Huang. Roles of the MYST Family in the Pathogenesis of Alzheimer’s Disease via Histone or Non-histone Acetylation[J]. Aging and disease, 2021, 12(1): 132-142.
[2] Xingzhi Guo,Yanying Liu,David Morgan,Li-Ru Zhao. Reparative Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor in Aged APP/PS1 Mice[J]. Aging and disease, 2020, 11(6): 1423-1443.
[3] Yan Zhao,Jun-Kun Zhan,Youshuo Liu. A Perspective on Roles Played by Immunosenescence in the Pathobiology of Alzheimer's Disease[J]. Aging and disease, 2020, 11(6): 1594-1607.
[4] Yaping Shao,Yang Ouyang,Tianbai Li,Xinyao Liu,Xiaojiao Xu,Song Li,Guowang Xu,Weidong Le. Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease[J]. Aging and disease, 2020, 11(6): 1459-1470.
[5] Rohan Mishra,Bin Li. The Application of Artificial Intelligence in the Genetic Study of Alzheimer’s Disease[J]. Aging and disease, 2020, 11(6): 1567-1584.
[6] Wenbo Li,Ling Kui,Tsirukis Demetrios,Xun Gong,Min Tang. A Glimmer of Hope: Maintain Mitochondrial Homeostasis to Mitigate Alzheimer’s Disease[J]. Aging and disease, 2020, 11(5): 1260-1275.
[7] Chi Him Poon,Yingyi Wang,Man-Lung Fung,Chengfei Zhang,Lee Wei Lim. Rodent Models of Amyloid-Beta Feature of Alzheimer’s Disease: Development and Potential Treatment Implications[J]. Aging and disease, 2020, 11(5): 1235-1259.
[8] Kan Yin Wong,Jaydeep Roy,Man Lung Fung,Boon Chin Heng,Chengfei Zhang,Lee Wei Lim. Relationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer’s Disease[J]. Aging and disease, 2020, 11(5): 1291-1316.
[9] Wei-Xing Ma,Jing Tang,Zhi-Wen Lei,Chun-Yan Li,Li-Qing Zhao,Chao Lin,Tao Sun,Zheng-Yi Li,Ying-Hui Jiang,Jun-Tao Jia,Cheng-Zhu Liang,Jun-Hong Liu,Liang-Jun Yan. Potential Biochemical Mechanisms of Brain Injury in Diabetes Mellitus[J]. Aging and disease, 2020, 11(4): 978-987.
[10] Seong Gak Jeon, Anji Yoo, Dong Wook Chun, Sang Bum Hong, Hyunju Chung, Jin-il Kim, Minho Moon. The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer’s Disease-related Pathogenesis[J]. Aging and disease, 2020, 11(3): 705-724.
[11] Yongming Jia, Na Wang, Yingbo Zhang, Di Xue, Haoming Lou, Xuewei Liu. Alteration in the Function and Expression of SLC and ABC Transporters in the Neurovascular Unit in Alzheimer’s Disease and the Clinical Significance[J]. Aging and disease, 2020, 11(2): 390-404.
[12] Yanfang Zhao, Yuan Zhang, Lei Zhang, Yanhan Dong, Hongfang Ji, Liang Shen. The Potential Markers of Circulating microRNAs and long non-coding RNAs in Alzheimer's Disease[J]. Aging and disease, 2019, 10(6): 1293-1301.
[13] Jie Zhang, Lijun Wang, Xia Deng, Guoqiang Fei, Lirong Jin, Xiaoli Pan, Liuhan Cai, Anthony D Albano, Chunjiu Zhong. Five-Minute Cognitive Test as A New Quick Screening of Cognitive Impairment in The Elderly[J]. Aging and disease, 2019, 10(6): 1258-1269.
[14] Piotr Gronek, Stefan Balko, Joanna Gronek, Adam Zajac, Adam Maszczyk, Roman Celka, Agnieszka Doberska, Wojciech Czarny, Robert Podstawski, Cain C. T Clark, Fang Yu. Physical Activity and Alzheimer’s Disease: A Narrative Review[J]. Aging and disease, 2019, 10(6): 1282-1292.
[15] Yingnan Xue, Zhenhua Zhang, Caiyun Wen, Huiru Liu, Suyuan Wang, Jiance Li, Qichuan Zhuge, Weijian Chen, Qiong Ye. Characterization of Alzheimer’s Disease Using Ultra-high b-values Apparent Diffusion Coefficient and Diffusion Kurtosis Imaging[J]. Aging and disease, 2019, 10(5): 1026-1036.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd